Sobal Corporation (2186)
Market Closed
17 Jul, 06:00
¥
914. 00
+1
+0.1095%
¥
- Market Cap
- P/E Ratio
- Div Yield
4,200 Volume
- Eps
¥ 913
Previous Close Want to track 2186 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
2186 closed yesterday higher at ¥914, an increase of 0.1095% from Thursday's close, completing a monthly increase of 0.3293% or ¥3. Over the past 12 months, 2186 stock gained 0.883%.
2186 pays dividends to its shareholders, with the most recent payment made on Feb 26, 2026. The next announced payment will be in In 1 month on Aug 28, 2026 for a total of ¥16.5.
The last earnings report, released on Apr 10, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Sobal Corporation has completed 2 stock splits, with the recent split occurring on Aug 29, 2017.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on HKEX (HKD).
2186 Chart
Sobal Corporation (2186) FAQ
What is the stock price today?
The current price is ¥914.00.
On which exchange is it traded?
Sobal Corporation is listed on JPX.
What is its stock symbol?
The ticker symbol is 2186.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Sobal Corporation ever had a stock split?
Sobal Corporation had 2 splits and the recent split was on Aug 29, 2017.
Sobal Corporation Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Mr. Dian Bo Liu CEO | JPX Exchange | JP3431520000 ISIN |
| DE Country | 5,115 Employees | - Last Dividend | - Last Split | - IPO Date |
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; and Seroquel, Seroquel XR, Erzofri, Rivastigmine Multi-Day Transdermal Patch, and Rivastigmine. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; and Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company distributes and sells pharmaceutical drugs; research and development of antibody drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
Contact Information
Address: No. 15 Chuang Ye Road, Yantai, China, 264003
Phone: -
Website: https://www.luye.cn
